WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018032785) HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/032785    International Application No.:    PCT/CN2017/079871
Publication Date: 22.02.2018 International Filing Date: 10.04.2017
IPC:
C07K 19/00 (2006.01), C12N 15/62 (2006.01), C12N 15/63 (2006.01), C12N 15/85 (2006.01), C12N 5/10 (2006.01), A61K 38/18 (2006.01), A61P 3/04 (2006.01), A61P 3/06 (2006.01), A61P 3/10 (2006.01)
Applicants: AMPSOURCE BIOPHARMA INC. [CN/CN]; Room 106, No.518, BiBo Road Pudong New Area Shanghai 201203 (CN)
Inventors: DONG, Zhao; (CN).
ZHOU, Chi; (CN).
FENG, Xiong; (CN).
LI, Zirui; (CN).
LI, Yuanli; (CN).
LI, Qiang; (CN)
Priority Data:
201610694914.1 19.08.2016 CN
Title (EN) HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
(FR) PROTÉINE DE FUSION DU FACTEUR 21 DE CROISSANCE DES FIBROBLASTES HUMAINS (HFGF21), SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 人成纤维细胞生长因子21融合蛋白及其制备方法与用途
Abstract: front page image
(EN)A fusion protein of hFGF21 or its analogs having improved pharmaceutical properties, and use of the fusion protein in preparing medicines for treating diseases, such as diabetes, obesity, non-alcoholic fatty liver disease, dyslipidemia, and/or metabolic syndrome.
(FR)L'invention concerne une protéine de fusion de hFGF21 ou ses analogues ayant des propriétés pharmaceutiques améliorées, et l'utilisation de la protéine de fusion dans la préparation de médicaments pour le traitement de maladies, tels que le diabète, l'obésité, la stéatose hépatique non alcoolique, la dyslipidémie et/ou le syndrome métabolique.
(ZH)具有改善的药学性质的人成纤维细胞生长因子21(hFGF21)或其类似物的融合蛋白,以及所述融合蛋白在制备治疗糖尿病、肥胖、非酒精性脂肪肝病、异常脂血症和/或代谢综合征等病症药物中的用途。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)